Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.

Cancer science - 1 Oct 2020

Seto Takashi, Hayashi Hidetoshi, Satouchi Miyako, Goto Yasushi, Niho Seiji, Nogami Naoyuki, Hida Toyoaki, Takahashi Toshiaki, Sakakibara-Konishi Jun, Morise Masahiro, Nagasawa Takashi, Suzuki Mie, Ohkura Masayuki, Fukuhara Kei, Thurm Holger, Peltz Gerson, Nishio Makoto

Abstract excerpt

Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS proto-oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) that is active against most known resistance mutations. This is an ongoing phase 1/2, multinational study (NCT01970865) investigating the efficacy, safety and pharmacokinetics of lorlatinib in ALK-rearranged/ROS1-rearranged advanced non-small cell lung cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Drug-Related Side Effects and Adverse Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypercholesterolemia

Share to Lactams

Share to Lactams, Macrocyclic

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Mas

Share to Pyrazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 32681682
DOI: 10.1111/cas.14576
PMCID: PMC7540988

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.PMID 32681682Read ↗

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.Semantic proximity Read ↗

A user’s guide to lorlatinibSemantic proximity Read ↗

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to dateSemantic proximity Read ↗

Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer.Semantic proximity Read ↗

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Alectinib for treatment of ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.Semantic proximity Read ↗

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.Semantic proximity Read ↗

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.Semantic proximity Read ↗

[Clinical research of crizotinib in advanced non-small cell lung cancer].Semantic proximity Read ↗

Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.Semantic proximity Read ↗

A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.